Chronic myelogenous leukemia, version 1.2015

Susan O'Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu V.B. Reddy, Neil P. Shah, B. Douglas Smith, David S. SnyderMeir Wetzler, Kristina Gregory, Hema Sundar

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

Original languageEnglish (US)
Pages (from-to)1590-1610
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Protein-Tyrosine Kinases
Transplants
Hematopoietic Stem Cells
Guidelines
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., ... Sundar, H. (2014). Chronic myelogenous leukemia, version 1.2015. JNCCN Journal of the National Comprehensive Cancer Network, 12(11), 1590-1610. https://doi.org/10.6004/jnccn.2014.0159

Chronic myelogenous leukemia, version 1.2015. / O'Brien, Susan; Radich, Jerald P.; Abboud, Camille N.; Akhtari, Mojtaba; Altman, Jessica K.; Berman, Ellin; Curtin, Peter; DeAngelo, Daniel J.; Deininger, Michael; Devine, Steven; Fathi, Amir T.; Gotlib, Jason; Jagasia, Madan; Kropf, Patricia; Moore, Joseph O.; Pallera, Arnel; Reddy, Vishnu V.B.; Shah, Neil P.; Smith, B. Douglas; Snyder, David S.; Wetzler, Meir; Gregory, Kristina; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 11, 01.11.2014, p. 1590-1610.

Research output: Contribution to journalArticle

O'Brien, S, Radich, JP, Abboud, CN, Akhtari, M, Altman, JK, Berman, E, Curtin, P, DeAngelo, DJ, Deininger, M, Devine, S, Fathi, AT, Gotlib, J, Jagasia, M, Kropf, P, Moore, JO, Pallera, A, Reddy, VVB, Shah, NP, Smith, BD, Snyder, DS, Wetzler, M, Gregory, K & Sundar, H 2014, 'Chronic myelogenous leukemia, version 1.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 11, pp. 1590-1610. https://doi.org/10.6004/jnccn.2014.0159
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E et al. Chronic myelogenous leukemia, version 1.2015. JNCCN Journal of the National Comprehensive Cancer Network. 2014 Nov 1;12(11):1590-1610. https://doi.org/10.6004/jnccn.2014.0159
O'Brien, Susan ; Radich, Jerald P. ; Abboud, Camille N. ; Akhtari, Mojtaba ; Altman, Jessica K. ; Berman, Ellin ; Curtin, Peter ; DeAngelo, Daniel J. ; Deininger, Michael ; Devine, Steven ; Fathi, Amir T. ; Gotlib, Jason ; Jagasia, Madan ; Kropf, Patricia ; Moore, Joseph O. ; Pallera, Arnel ; Reddy, Vishnu V.B. ; Shah, Neil P. ; Smith, B. Douglas ; Snyder, David S. ; Wetzler, Meir ; Gregory, Kristina ; Sundar, Hema. / Chronic myelogenous leukemia, version 1.2015. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 11. pp. 1590-1610.
@article{a45ae5505a364f5f8d636c96d2962b07,
title = "Chronic myelogenous leukemia, version 1.2015",
abstract = "Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.",
author = "Susan O'Brien and Radich, {Jerald P.} and Abboud, {Camille N.} and Mojtaba Akhtari and Altman, {Jessica K.} and Ellin Berman and Peter Curtin and DeAngelo, {Daniel J.} and Michael Deininger and Steven Devine and Fathi, {Amir T.} and Jason Gotlib and Madan Jagasia and Patricia Kropf and Moore, {Joseph O.} and Arnel Pallera and Reddy, {Vishnu V.B.} and Shah, {Neil P.} and Smith, {B. Douglas} and Snyder, {David S.} and Meir Wetzler and Kristina Gregory and Hema Sundar",
year = "2014",
month = "11",
day = "1",
doi = "10.6004/jnccn.2014.0159",
language = "English (US)",
volume = "12",
pages = "1590--1610",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

TY - JOUR

T1 - Chronic myelogenous leukemia, version 1.2015

AU - O'Brien, Susan

AU - Radich, Jerald P.

AU - Abboud, Camille N.

AU - Akhtari, Mojtaba

AU - Altman, Jessica K.

AU - Berman, Ellin

AU - Curtin, Peter

AU - DeAngelo, Daniel J.

AU - Deininger, Michael

AU - Devine, Steven

AU - Fathi, Amir T.

AU - Gotlib, Jason

AU - Jagasia, Madan

AU - Kropf, Patricia

AU - Moore, Joseph O.

AU - Pallera, Arnel

AU - Reddy, Vishnu V.B.

AU - Shah, Neil P.

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Wetzler, Meir

AU - Gregory, Kristina

AU - Sundar, Hema

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

AB - Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

UR - http://www.scopus.com/inward/record.url?scp=84908539399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908539399&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0159

DO - 10.6004/jnccn.2014.0159

M3 - Article

C2 - 25361806

AN - SCOPUS:84908539399

VL - 12

SP - 1590

EP - 1610

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 11

ER -